ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Time
9,412 announcements with these filters
Q2 FY27 consolidated revenue INR 296 Cr (+42%), EBITDA INR 45 Cr (+51%), PAT INR 8 Cr (+144%). Battery Chemicals revenue INR 37 Cr; Organolithium capacity expansion approved.
Q2 FY27 consolidated revenue ₹40,475 Cr (+11.4%), EBITDA ₹21,879 Cr (+16.6%), margin 54.1%, PAT ₹8,387 Cr (+13.7%). Strong operating leverage, but ARPU growth is modest at 3.5%.
H1 FY27 revenue ₹213.3 Cr (+73%), PAT ₹20.0 Cr (+69%); Q2 revenue ₹134.9 Cr (+112%), PAT ₹12.5 Cr. Scaling T&D and solar EPC toward ₹1,000 Cr FY28 revenue target.
Record Q2: consolidated EBITDA ₹62,409 Cr (+24%) and PAT near ₹30,000 Cr (+34%), driven by an O2C windfall from energy disruption. Retail EBITDA fell about 11%.
Q2 FY27 consolidated revenue Rs 285.5 Cr (+38.7%), PAT Rs 63.3 Cr (+80.1%), EBITDA margin 28.6%. H1 Total Income Rs 550 Cr (+33.2%). Order book ~Rs 2,010 Cr.
Q2 FY27 total income ₹372 Cr (2.3x YoY), EBITDA ₹340 Cr at 91% margin, reported PAT ₹31 Cr after ₹23 Cr one-offs. Strategy centres on FDRE, wind and BESS scale-up.
Q2FY27 operating revenue ₹241.5 Cr (+3.9%), EBITDA ₹49.2 Cr (+23.9%), margin 20.4% (+331 bps). H1 revenue ₹478.0 Cr (+13.0%); Paramount integration complete.
Q2 FY27 consolidated revenue ₹3,887 Cr (+73% YoY), EBITDA ₹418 Cr (+44%), PAT ₹169 Cr (+60%); H1 PAT ₹324 Cr (+117%). Zone IV commercialisation and a 10+ year supply deal anchor growth.
Q2/H1 FY27 deck (Sep 2026) gives no quarterly P&L figures. Highlights: 302 products, 599 registrations, FY26 export share 63%, Saicriti injectable and Noumed acquisitions.
Q2 FY27 revenue INR 541 Cr, up 26% YoY, a record quarter. EBITDA margin fell to 2.4% (down 290 bps) and the company posted a PAT loss of INR 2.5 Cr on input-cost pressure.
Q2FY27 revenue ₹23.29 Cr (-23% YoY, +62% QoQ), EBITDA margin 16.9%, PAT ₹1.63 Cr (-67% YoY). Sequential recovery; CRAMS and new products progressing.
Q2FY27 consolidated revenue ₹345.13 Cr (+98.8% YoY), Operational EBITDA ₹131.99 Cr (38.2% margin), adj PAT ₹89.54 Cr (+50.7%). Order book ₹1,375.70 Cr; indigenous defence technology focus.
Q2 FY27 revenue fell 21% to ₹407 Cr on weak monsoon demand, but EBITDA rose 30% to ₹101 Cr (25% margin) and PAT rose 48% to ₹57 Cr, driven by a higher patented mix.
Q2 FY27 consolidated revenue ₹220.9 Cr (+40.8% YoY), EBITDA ₹31.9 Cr (14.46% margin), PAT ₹19.2 Cr (+88.5%). Order book ₹1,574.8 Cr, up 47% YoY.
Q2FY27 revenue Rs415cr (+16% YoY), EBITDA Rs71cr (-1%), PAT Rs50cr (-11.4%). H1FY27 revenue Rs773cr (+11.3%), PAT Rs95cr (-11.9%). Growth led by Banking and TIG.
H1 FY27 standalone revenue ₹30.36 Cr (+44% YoY), PAT ₹6.76 Cr (+22.5%), EBITDA margin 32.42%. Consolidated revenue ₹40.10 Cr. Zero bank debt; ₹48.4 Cr order inflow.
Q2 FY27 revenue ₹821cr (+11% YoY), EBITDA ₹202cr (24.7% margin), PAT ₹127cr (+19% YoY). Vacuum salt live; bromine commissioned Oct 2026.
Q2 FY27 revenue ₹615 Mn (+12% YoY) but EBITDA fell to ₹19 Mn (3.1% margin) and PAT was a ₹6 Mn loss on raw material costs and higher depreciation.
Q2FY27 revenue ₹1,835.29Mn (+16.5%) and PAT ₹65.36Mn (+22.2%). H1FY27 revenue ₹3,302.56Mn (+33.1%), EBITDA ₹214.58Mn (+34%), PAT ₹130.07Mn (+62.18%).
Q2 FY27 consolidated revenue Rs16,080Mn (+22.9% YoY); EBITDA Rs1,409Mn at 8.8% margin, down ~80bps YoY. Forvia PV seat JV announced.
Q2 FY27: revenue from operations ₹2,941Mn (+14.2% YoY), adjusted EBITDA ₹608Mn at 20.7% margin (-1.9pp YoY), reported PAT ₹485Mn (+6.1% YoY). Data and AI focus.
Q2FY27 consolidated revenue ₹513.0 Cr (+41% YoY), EBITDA ₹60.7 Cr at 11.8% margin, PAT ₹28.1 Cr. H1 PAT ₹57.1 Cr. Standalone PAT ₹14.5 Cr.
KFIL (listed material subsidiary) Q2 FY27 standalone: revenue ₹2,047 Cr (+17% YoY), PAT ₹98 Cr (+10%), EBITDA margin 10.9% (vs 12.2%).
H1 FY27 revenue from operations ₹42.6 Cr, EBITDA ₹9.9 Cr, PAT ₹5.1 Cr. No YoY comparatives or quantified guidance disclosed.
Q2 FY27 revenue INR 1,745 Mn (+7.3% YoY), PAT INR 165 Mn (+52.8%), EBITDA margin 17.54%. Pure-play MCGM redevelopment, asset-light model.
Q2 FY27 standalone revenue ₹227.8cr (+11.6% YoY), PAT ₹126.7cr (+5.2%). Consolidated revenue +36.5%, PAT +10.9%. Focus on DEMAT 2.0, tokenised bonds and NPBL growth.
Q2FY27 revenue ₹183.1 Cr (+18.6%), PAT ₹14.7 Cr (-28.5%); H1FY27 revenue ₹352.8 Cr (+16.2%), PAT ₹27.0 Cr (-33.8%) on raw-material cost spike.
Q2 FY27 consolidated revenue ₹548 Cr (+23% YoY) and PAT ₹84 Cr (+11%). Post-IndAS EBITDA margin fell to 31.0% from 33.5%. Strategy is hub-and-spoke pediatric and maternity expansion across 26 hospitals.
H1 FY27 consolidated revenue ₹133.23 Cr (+75%), PAT ₹5.15 Cr (+55%), EBITDA margin 7.67%. Order book ₹468 Cr, 2.35x since Mar 2026.
H1 FY27 consolidated revenue +54.87% to ₹171.22 Cr; PAT ₹3.45 Cr from ₹0.19 Cr. EBITDA +43% but margin slipped; management gives no numeric guidance.